Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16902790 | 0.88 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL5644491 | 0.88 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL16893833 | 0.85 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL16893830 | 0.85 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL5645571 | 0.85 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL16902795 | 0.84 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL16893930 | 0.84 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL16893929 | 0.84 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL16893571 | 0.83 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL16893575 | 0.83 | PTGS2 (0.81) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | ARG1, ARGLU1, CGAS | PTGS2 1336/4885PTGS1 901/4885 |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | NOS1, NOS2, NOS3 | PTGS2 608/4885PTGS1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.